9.79
+0.0642(+0.66%)
Currency In USD
| Previous Close | 9.73 |
| Open | 9.94 |
| Day High | 10.06 |
| Day Low | 9.66 |
| 52-Week High | 16.54 |
| 52-Week Low | 5.64 |
| Volume | 620,558 |
| Average Volume | 1.6M |
| Market Cap | 1.01B |
| PE | -6.44 |
| EPS | -1.52 |
| Moving Average 50 Days | 7.38 |
| Moving Average 200 Days | 7.77 |
| Change | 0.06 |
If you invested $1000 in Day One Biopharmaceuticals, Inc. (DAWN) since IPO date, it would be worth $416.77 as of November 10, 2025 at a share price of $9.794. Whereas If you bought $1000 worth of Day One Biopharmaceuticals, Inc. (DAWN) shares 3 years ago, it would be worth $468.62 as of November 10, 2025 at a share price of $9.794.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
GlobeNewswire Inc.
3 hours ago
Three-year follow-up data from FIREFLY-1 demonstrates durable responses with evidence of clinical stability off treatment, with the potential for retreatment after progression Treatment-free interval data to also be disclosed for the first time BRISB
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
GlobeNewswire Inc.
Oct 21, 2025 12:30 PM GMT
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
GlobeNewswire Inc.
Jul 22, 2025 12:30 PM GMT
BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-